Plain-English translation of NCT07280468 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Sleep apnea is extremely common in people with Down syndrome and can affect thinking and quality of life. This study is testing whether atomoxetine and oxybutynin (a combination of two medications) given to everyone works as well as choosing between this medication or therapy based on each person's individual sleep test results. The goal is to find out if personalizing treatment — rather than giving everyone the same medicine — leads to better outcomes.
Current treatments for sleep apnea in people with Down syndrome don't work well enough. Surgery often doesn't fully solve the problem, and many people stop using breathing machines because they're hard to stick with. This medication combination shows promise, but doesn't help everyone equally. This trial exists to figure out if matching the right treatment to each person's unique sleep pattern could be more effective.
You likely qualify if…
You likely don't qualify if…
Half of participants will take the medication combination nightly, while the other half will be assigned to whichever treatment (the medication or ) the researchers predict will work best based on their sleep study. Participants will take their assigned treatment at home each night and attend visits to check how well it's working, answer questions about sleep quality and daytime energy, and have follow-up sleep tests to measure improvement.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States